LifeMD Reports Second Quarter 2026 Results
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3 million, down from $49.0 million but within guidance, and an adjusted EBITDA loss of about $3.5 million, a ~21% sequential improvement. Gross margin expanded ~280 basis points year-over-year to ~89%, with about 84% of revenue from recurring subscriptions.
Active subscribers rose 20% year-over-year to ~356,000, including ~108,000 Weight Management Program subscribers, as ~95% of new weight management patients began branded GLP-1 therapies. LifeMD ended the quarter with $25.1 million in cash, no debt, and $30 million of undrawn revolver capacity. The company cut full-year 2026 guidance to $205.5–$212.5 million revenue and adjusted EBITDA of negative $6.0 million to breakeven, but still targets a Q4 2026 annualized exit run rate of about $250 million revenue and roughly $22 million of annualized adjusted EBITDA before estimated XYOSTED launch costs.
Positive
- Gross margin ~89%, up ~280 bps year-over-year in Q2 2026
- Active subscribers +20% YoY to ~356,000; weight management at ~108,000
- Recurring revenue 84% of Q2 2026 total, supporting visibility
- Cash $25.1 million and no debt, plus $30 million undrawn revolver
- Marketing and G&A costs declined sequentially by $1.8m and ~$2.2m respectively
- Q4 2026 outlook: $60–$64m revenue and $3–$6m adjusted EBITDA, implying ~$250m run-rate
Negative
- Revenue down to $47.3m from $49.0m year-over-year in Q2 2026
- GAAP net loss widened to $7.9m from $3.8m in continuing operations
- Adjusted EBITDA swung to a ~$3.5m loss from ~$3.9m profit year-over-year
- Selling and marketing +27% YoY to $28.0m despite lower revenue
- 2026 revenue guidance cut to $205.5–$212.5m from $220–$230m
- 2026 adjusted EBITDA guidance reduced to -$6.0m to breakeven from $12–$17m
News Explained
The report adds a larger common-share denominator and a higher Q2 loss attributable to common holders; Q3 guidance is the next stated profitability checkpoint.
The company has reported its second-quarter results, and its balance sheet shows 47,820,492 common shares outstanding at
The quarter also produced a GAAP net loss attributable to common stockholders of
The next stated checkpoint is the
Market reaction after 2Q26 earnings report: LFMD -7.34%
Following this news, LFMD has declined 7.34%, reflecting a notable negative market reaction. Our momentum scanner has triggered 11 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $3.41. Trading volume is elevated at 2.6x the average, suggesting increased selling activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 earnings report | Positive | -14.8% | Revenue and EBITDA were in line while margins, subscribers, and guidance improved. |
| Mar 09 | FY earnings report | Positive | +25.3% | Strong quarterly and full-year growth accompanied improved EBITDA and cash position. |
| Nov 17 | Q3 earnings report | Positive | -13.5% | Revenue and EBITDA growth followed debt repayment and reduced full-year guidance. |
| Aug 05 | Q2 earnings report | Negative | -44.9% | Strong segment growth coincided with reduced full-year revenue and EBITDA guidance. |
| Aug 04 | Peer earnings report | Negative | -4.1% | Revenue, coach count, and guidance declined amid GLP-1 competitive pressure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings history averaged a -10.4% move, with three aligned and two divergent reactions; positive earnings outcomes sometimes coincided with negative reactions.
Key Terms
glp-1 therapies medical
adjusted ebitda financial
subcutaneous medical
revolving credit facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Second quarter 2026 revenue of
$47.3 million , within the Company’s guidance range of$47 million to$50 million ; adjusted EBITDA loss of approximately$3.5 million , improving approximately21% sequentially. - Approximately
95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications. - Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately
89% , reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy. - Weight Management Program subscribers grew to approximately 108,000 at quarter end; total active subscribers increased
20% year-over-year to approximately 356,000. - Women’s Health operating trends continues to improve, with lower customer acquisition costs and a broad set of new pharmacy products launching in the second half.
- Launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED®, the only FDA-approved, once-weekly subcutaneous testosterone auto-injector — with additional strategic partnerships and enterprise relationships advancing toward execution in the second half of 2026.
- Exited the quarter with
$25.1 million of cash, no debt, and$30 million of additional liquidity under its revolving credit facility. - Expecting a return to positive adjusted EBITDA in the second half of 2026 and an expected fourth quarter exit revenue run rate of approximately
$250 million and approximately$22 million of annualized adjusted EBITDA - Revising full year 2026 guidance to revenue of
$205.5 million to$212.5 million and adjusted EBITDA of negative$6.0 million to breakeven, including$2 million to$3 million of net launch costs for XYOSTED® in 2026.
Conference call begins at 4:30 p.m. Eastern time today
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today reported financial results for the second quarter ended June 30, 2026.
Management Commentary
“Revenue of
“Our model remains simple: Quality Care. Quality Products. Quality Revenue. We are building around longer patient relationships and a more diversified acquisition model, with increasing contributions over time from pharmaceutical manufacturers, employers, insurers, Medicare, referrals, and cross-care within our existing patient base. Following the pricing change in weight management, the share of new patients selecting multi-month packages increased from approximately
“This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company that is more diversified. We are also encouraged by the progress we are seeing in Women’s Health, the launch of XYOSTED® with Halozyme, the continued expansion of our pharmacy, and the development of our pharmaceutical, enterprise, insurance, and Medicare channels. We expect to return to positive adjusted EBITDA in the second half and to exit 2026 at an annualized revenue run rate of approximately
“The second quarter reflected the planned step-down in marketing investment we described on our last call, with selling and marketing expense declining
Second Quarter 2026 Financial Highlights
All comparisons are with the second quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.
- Total revenue was
$47.3 million compared with$49.0 million in the prior-year period, reflecting the continued shift from compounded to branded GLP-1 therapies and lower upfront revenue associated with the Company’s pricing and mix decisions. - Approximately
84% of revenue was derived from recurring subscriptions. - The number of active subscribers increased
20% to approximately 356,000 at quarter end. - At quarter end, the number of Weight Management Program subscribers was approximately 108,000, up from just under 100,000 at the end of the first quarter of 2026.
- Gross profit was
$42.0 million , essentially flat with the prior-year period despite lower revenue; gross margin expanded to approximately89% , compared to86% in the prior-year period, primarily due to lower shipping and fulfillment costs and the continued scaling of the Company’s affiliated pharmacy. - Selling and marketing expenses increased
27% year-over-year to$28.0 million , but declined$1.8 million from the first quarter of 2026, consistent with the planned sequential step-down in patient acquisition spend. - General and administrative expenses declined
5% to$13.6 million , led by lower employee expenses and legal and professional services fees. - GAAP net loss from continuing operations attributable to common stockholders was
$7.9 million , or$0.16 per share, compared with a GAAP net loss from continuing operations attributable to common stockholders of$3.8 million , or$0.09 per share, in the prior-year period. - Adjusted EBITDA loss was approximately
$3.5 million , compared with adjusted EBITDA of approximately$3.9 million in the prior-year period, reflecting elevated customer acquisition costs earlier in the quarter and lower upfront cash collection associated with the Company’s$39 introductory offer; monthly performance improved as the quarter progressed. - Cash totaled
$25.1 million as of June 30, 2026, and the Company had no debt at quarter end, with an undrawn$30 million revolving credit facility.
Second Quarter Key Performance Metrics
Positioned for a Strong Second Half
LifeMD enters the second half with improving acquisition trends, a growing recurring patient base, and a broader set of growth channels taking shape. Priorities for the remainder of 2026 include scaling longer-duration weight management memberships, expanding Women’s Health and the XYOSTED® collaboration, increasing pharmacy attachment, and advancing pharmaceutical, insurance, Medicare, employer, and enterprise relationships. Together, these initiatives should reduce reliance on paid media, deepen patient relationships, and support improving operating leverage and financial performance through year-end.
Financial Guidance
For the third quarter of 2026, the Company expects:
- Revenue in the range of
$48 million to$51 million . - Adjusted EBITDA in the range of negative
$1 million to positive$2 million , returning to positive adjusted EBITDA as cost savings take hold and the Company’s recurring rebill base continues to build.
For the full year 2026, the Company expects (revised from previous guidance):
- Revenue in the range of
$205.5 million to$212.5 million , compared with previous guidance of$220 million to$230 million . - Adjusted EBITDA in the range of negative
$6.0 million to breakeven, compared with previous guidance of$12 million to$17 million . - The Company’s fourth quarter 2026 guidance of
$60 million to$64 million of revenue and$3 million to$6 million of adjusted EBITDA implies an annualized exit run rate of approximately$250 million of revenue and before estimated XYOSTED® launch costs, approximately$22 million of continuing adjusted EBITDA.
Conference Call
LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:
| Toll-free dial-in number: | (800) 715-9871 |
| International dial-in number: | +1 (646) 307-1963 |
| Conference ID: | 3616168 (“LifeMD, Inc. Second Quarter 2026 Results”) |
A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.
About LifeMD, Inc.
LifeMD® is a leading virtual care company making high-quality healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, a state-of-the-art in-house pharmacy, and a U.S.-based patient care center. Together, these capabilities support care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
ir@lifemd.com
Media Contact
press@lifemd.com
| LIFEMD, INC. | |||||
| CONSOLIDATED BALANCE SHEETS | |||||
| (Unaudited) | |||||
| June 30, 2026 | December 31, 2025 | ||||
| ASSETS | |||||
| Current Assets | |||||
| Cash | $ | 25,141,615 | $ | 36,786,318 | |
| Accounts receivable | 11,256,158 | 9,305,277 | |||
| Product deposit | 243,759 | 320,217 | |||
| Inventory, net | 2,956,144 | 2,773,576 | |||
| Other current assets | 2,486,803 | 2,646,077 | |||
| Total Current Assets | 42,084,479 | 51,831,465 | |||
| Non-current Assets | |||||
| Equipment, net | 2,035,475 | 2,444,717 | |||
| Right of use assets, net | 4,839,958 | 5,267,857 | |||
| Capitalized software, net | 10,734,486 | 10,604,946 | |||
| Intangible assets, net | 198,500 | 262,334 | |||
| Total Non-current Assets | 17,808,419 | 18,579,854 | |||
| Total Assets | $ | 59,892,898 | $ | 70,411,319 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
| Current Liabilities | |||||
| Accounts payable | $ | 18,156,912 | $ | 14,149,154 | |
| Accrued expenses | 16,961,186 | 15,974,016 | |||
| Current operating lease liabilities | 699,511 | 642,422 | |||
| Deferred revenue | 10,791,221 | 10,807,773 | |||
| Total Current Liabilities | 46,608,830 | 41,573,365 | |||
| Long-term Liabilities | |||||
| Noncurrent operating lease liabilities | 5,317,613 | 5,681,374 | |||
| Total Liabilities | 51,926,443 | 47,254,739 | |||
| Commitments and Contingencies | |||||
| Stockholders’ Equity | |||||
| Series A Preferred Stock, | 140 | 140 | |||
| Common Stock, | 479,235 | 467,600 | |||
| Additional paid-in capital | 253,763,518 | 251,455,616 | |||
| Accumulated deficit | (246,112,737) | (228,603,075) | |||
| Treasury stock, 103,040 shares, at cost, as of June 30, 2026 and December 31, 2025 | (163,701) | (163,701) | |||
| Total Stockholders’ Equity | 7,966,455 | 23,156,580 | |||
| Total Liabilities and Stockholders’ Equity | $ | 59,892,898 | $ | 70,411,319 | |
| LIFEMD, INC. | ||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Telehealth revenue, net | $ | 47,281,085 | $ | 49,018,882 | $ | 97,444,041 | $ | 99,906,781 | ||||
| Cost of telehealth revenue | 5,284,323 | 6,838,703 | 11,209,822 | 14,975,164 | ||||||||
| Gross profit | 41,996,762 | 42,180,179 | 86,234,219 | 84,931,617 | ||||||||
| Expenses | ||||||||||||
| Selling and marketing expenses | 28,035,947 | 22,151,114 | 57,910,807 | 44,424,036 | ||||||||
| General and administrative expenses | 13,645,809 | 14,439,140 | 28,822,164 | 28,779,294 | ||||||||
| Other operating expenses | 3,040,187 | 2,883,015 | 6,220,133 | 5,272,551 | ||||||||
| Customer service expenses | 2,612,986 | 3,230,735 | 5,752,291 | 6,302,229 | ||||||||
| Development costs | 1,791,434 | 1,823,061 | 3,587,497 | 3,682,110 | ||||||||
| Total expenses | 49,126,363 | 44,527,065 | 102,292,892 | 88,460,220 | ||||||||
| Operating loss from continuing operations | (7,129,601) | (2,346,886) | (16,058,673) | (3,528,603) | ||||||||
| Interest income (expense), net | 45,660 | (660,787) | 102,136 | (1,124,425) | ||||||||
| Loss from continuing operations before income taxes | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) | ||||||||
| Income tax provision | - | - | - | - | ||||||||
| Net loss from continuing operations | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) | ||||||||
| Net income from discontinued operations | - | 1,893,084 | - | 3,886,506 | ||||||||
| Net loss | (7,083,941) | (1,114,589) | (15,956,537) | (766,522) | ||||||||
| Net income attributable to noncontrolling interests of discontinued operations | - | 505,075 | - | 1,036,920 | ||||||||
| Net loss attributable to LifeMD, Inc. | (7,083,941) | (1,619,664) | (15,956,537) | (1,803,442) | ||||||||
| Preferred stock dividends | (776,562) | (776,562) | (1,553,125) | (1,553,125) | ||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | (7,860,503) | $ | (2,396,226) | $ | (17,509,662) | $ | (3,356,567) | ||||
| Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholders | ||||||||||||
| Continuing operations | $ | (0.16) | $ | (0.09) | $ | (0.37) | $ | (0.14) | ||||
| Discontinued operations | - | 0.03 | - | 0.07 | ||||||||
| Basic loss per share | $ | (0.16) | $ | (0.05) | $ | (0.37) | $ | (0.08) | ||||
| Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholders | ||||||||||||
| Continuing operations | $ | (0.16) | $ | (0.09) | $ | (0.37) | $ | (0.14) | ||||
| Discontinued operations | - | 0.03 | - | 0.07 | ||||||||
| Diluted loss per share | $ | (0.16) | $ | (0.05) | $ | (0.37) | $ | (0.08) | ||||
| Weighted average number of common shares outstanding: | ||||||||||||
| Basic | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 | ||||||||
| Diluted | 47,788,194 | 44,401,531 | 47,563,376 | 43,772,151 | ||||||||
| LIFEMD, INC. | |||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
| (Unaudited) | |||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||
| Net loss | $ | (7,083,941) | $ | (1,114,589) | $ | (15,956,537) | $ | (766,522) | |||
| Less: Net income from discontinued operations | - | 1,893,084 | - | 3,886,506 | |||||||
| Net loss from continuing operations | (7,083,941) | (3,007,673) | (15,956,537) | (4,653,028) | |||||||
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: | |||||||||||
| Amortization of debt discount | - | 100,444 | - | 200,888 | |||||||
| Amortization of capitalized software | 1,713,679 | 1,586,322 | 3,388,532 | 3,115,702 | |||||||
| Amortization of intangibles | 31,917 | 23,500 | 63,834 | 30,167 | |||||||
| Depreciation of fixed assets | 292,787 | 175,523 | 582,245 | 330,884 | |||||||
| Noncash operating lease expense | 215,132 | 255,824 | 427,899 | 525,712 | |||||||
| Stock compensation expense | 790,112 | 2,094,614 | 2,239,017 | 4,643,142 | |||||||
| Changes in Assets and Liabilities | |||||||||||
| Accounts receivable | (1,401,041) | 1,973,894 | (1,950,881) | 1,513,946 | |||||||
| Product deposit | 87,766 | (59,160) | 76,458 | (210,237) | |||||||
| Inventory | 220,992 | (283,658) | (182,568) | (453,997) | |||||||
| Other current assets | 1,368,328 | 522,068 | 159,274 | 824,289 | |||||||
| Operating lease liabilities | (155,773) | (68,507) | (306,672) | (148,306) | |||||||
| Deferred revenue | (1,225,619) | (2,783,497) | (16,552) | (2,586,163) | |||||||
| Accounts payable | (3,496,210) | 8,573,302 | 4,007,758 | 8,487,929 | |||||||
| Accrued expenses | 1,716,223 | (3,001,387) | 987,170 | (5,260,493) | |||||||
| Net cash (used in) provided by operating activities of continuing operations | (6,925,648) | 6,101,609 | (6,481,023) | 6,360,435 | |||||||
| Net cash provided by operating activities of discontinued operations | - | 2,537,838 | - | 5,347,399 | |||||||
| Net cash (used in) provided by operating activities | (6,925,648) | 8,639,447 | (6,481,023) | 11,707,834 | |||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||
| Cash paid for capitalized software costs | (1,566,487) | (2,060,313) | (3,518,072) | (3,947,128) | |||||||
| Purchase of equipment | (67,825) | (776,670) | (173,003) | (894,215) | |||||||
| Net cash used in investing activities of continuing operations | (1,634,312) | (2,836,983) | (3,691,075) | (4,841,343) | |||||||
| Net cash used in investing activities of discontinued operations | - | (862,600) | - | (1,725,578) | |||||||
| Net cash used in investing activities | (1,634,312) | (3,699,583) | (3,691,075) | (6,566,921) | |||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||
| Repayment of debt instruments | - | (2,052,288) | - | (2,052,288) | |||||||
| Preferred stock dividends | (776,562) | (776,562) | (1,553,125) | (1,553,125) | |||||||
| Cash proceeds from exercise of options | - | - | 80,520 | - | |||||||
| Net cash used in financing activities of continuing operations | (776,562) | (2,828,850) | (1,472,605) | (3,605,413) | |||||||
| Net cash used in financing activities of discontinued operations | - | (276,119) | - | (312,119) | |||||||
| Net cash used in financing activities | (776,562) | (3,104,969) | (1,472,605) | (3,917,532) | |||||||
| Net (decrease) increase in cash | (9,336,522) | 1,834,895 | (11,644,703) | 1,223,381 | |||||||
| Cash at beginning of period | 34,478,137 | 34,393,410 | 36,786,318 | 35,004,924 | |||||||
| Cash at end of year | 25,141,615 | 36,228,305 | 25,141,615 | 36,228,305 | |||||||
| Less: Cash of discontinued operations at end of year | - | 3,216,945 | - | 3,216,945 | |||||||
| Cash of continuing operations at end of year | $ | 25,141,615 | $ | 33,011,360 | $ | 25,141,615 | $ | 33,011,360 | |||
| Cash paid for interest and taxes | |||||||||||
| Cash paid during the period for interest | $ | - | $ | 625,818 | $ | - | $ | 1,219,568 | |||
| Cash paid during the period for taxes | $ | 361,230 | $ | 445,158 | $ | 361,230 | $ | 467,854 | |||
| Non-cash investing and financing activities | |||||||||||
| Cashless exercise of options | $ | - | $ | 501 | $ | - | $ | 1,062 | |||
| Cashless exercise of warrants | $ | - | $ | 3,901 | $ | - | $ | 3,901 | |||
| Stock issued for debt conversion | $ | - | $ | 1,000,000 | $ | - | $ | 1,000,000 | |||
| Stock issued for asset acquisition | $ | - | $ | 303,000 | $ | - | $ | 303,000 | |||
| Reconciliation of Net Loss Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA | ||||||||||||
| (in whole numbers, unaudited) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | (7,860,503) | $ | (2,396,226) | $ | (17,509,662) | $ | (3,356,567) | ||||
| Interest (income) expense (excluding amortization of debt discount) | (45,660) | 560,343 | (102,136) | 923,537 | ||||||||
| Depreciation and amortization expense | 2,038,383 | 1,785,345 | 4,034,611 | 3,476,753 | ||||||||
| Amortization of debt discount | - | 100,444 | - | 200,888 | ||||||||
| Litigation costs (a) | 386,366 | 486,462 | 1,047,941 | 739,659 | ||||||||
| Severance and restructuring costs | 385,109 | 25,535 | 748,994 | 102,417 | ||||||||
| Acquisitions expenses | - | 1,806,277 | - | 2,014,777 | ||||||||
| Insurance acceptance readiness | - | 34,780 | - | 175,140 | ||||||||
| Preferred stock dividends | 776,562 | 776,562 | 1,553,125 | 1,553,125 | ||||||||
| Stock compensation expense | 790,112 | 2,094,614 | 2,239,017 | 4,643,142 | ||||||||
| Net income from discontinued operations | - | (1,893,084) | - | (3,886,506) | ||||||||
| Net income attributable to noncontrolling interests of discontinued operations | - | 505,075 | - | 1,036,920 | ||||||||
| Adjusted EBITDA | $ | (3,529,631) | $ | 3,886,127 | $ | (7,988,110) | $ | 7,623,285 | ||||
| (a) For the three and six months ended June 30, 2026, the Company included costs related to: (1) a class action complaint captioned Johnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, and (2) a heavily negotiated executive separation agreement. For the three and six months ended June 30, 2025, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), and a heavily negotiated executive separation agreement. | ||||||||||||
About the Use of Non-GAAP Financial Measures
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations and net income attributable to noncontrolling interests of discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.
We believe the above financial measure is commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
| Reconciliation of Net Loss Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA | ||||||||||||
| (in whole numbers, unaudited) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | (7,860,503) | $ | (2,396,226) | $ | (17,509,662) | $ | (3,356,567) | ||||
| Interest (income) expense (excluding amortization of debt discount) | (45,660) | 560,343 | (102,136) | 923,537 | ||||||||
| Depreciation and amortization expense | 2,038,383 | 1,785,345 | 4,034,611 | 3,476,753 | ||||||||
| Amortization of debt discount | - | 100,444 | - | 200,888 | ||||||||
| Litigation costs (a) | 386,366 | 486,462 | 1,047,941 | 739,659 | ||||||||
| Severance and restructuring costs | 385,109 | 25,535 | 748,994 | 102,417 | ||||||||
| Acquisitions expenses | - | 1,806,277 | - | 2,014,777 | ||||||||
| Insurance acceptance readiness | - | 34,780 | - | 175,140 | ||||||||
| Preferred stock dividends | 776,562 | 776,562 | 1,553,125 | 1,553,125 | ||||||||
| Stock compensation expense | 790,112 | 2,094,614 | 2,239,017 | 4,643,142 | ||||||||
| Net income from discontinued operations | - | (1,893,084) | - | (3,886,506) | ||||||||
| Net income attributable to noncontrolling interests of discontinued operations | - | 505,075 | - | 1,036,920 | ||||||||
| Adjusted EBITDA | $ | (3,529,631) | $ | 3,886,127 | $ | (7,988,110) | $ | 7,623,285 | ||||
| (a) For the three and six months ended June 30, 2026, the Company included costs related to: (1) a class action complaint captioned Johnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, and (2) a heavily negotiated executive separation agreement. For the three and six months ended June 30, 2025, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), and a heavily negotiated executive separation agreement. | ||||||||||||
